Does New Hampshire’s Addiction Treatment System Actually Work?

A Hard Look at Outcomes in the Fentanyl Era

For years, New Hampshire has been held up as both cautionary tale and partial success story in America’s opioid crisis. Overdose deaths are finally drifting down. Funding has exploded. The state has built The Doorway system, expanded Medicaid, and layered on grants and settlement dollars. But underneath all the ribbon-cuttings is the uncomfortable question Granite Staters actually care about: is the treatment system working — or just treading water while fentanyl keeps rewriting the rules?

1. What “Working” Should Mean — and Why We Rarely Measure It

When politicians talk about addiction treatment, they usually talk inputs: more beds, more grants, more money for programs.

Those things matter. But they are means, not ends.

If we’re serious, “success” in New Hampshire’s addiction system should be judged by outcomes like:

Overdose deaths: fewer people dying.
Retention in effective treatment, especially medication for opioid use disorder (MOUD) like methadone and buprenorphine.
Relapse and readmission: how many people cycle back into detox, residential, jail, or the ER.
Functional recovery: housing stability, employment, parenting, criminal legal involvement, quality of life.
Equity of access: how differently Medicaid, private insurance, and cash/self-pay patients experience the system.

Right now, New Hampshire tracks some of these, but not all, and almost never in a way that the public can translate into a simple answer to the question: does this system actually help people stay alive and rebuild their lives?

2. The Scoreboard: Overdoses, Treatment Use, and System Capacity

Overdose deaths: progress, but on a knife’s edge

According to the New Hampshire Information & Analysis Center, there were 430 drug overdose deaths in 2023, about a 12% drop from 2022 — the first decrease in several years. Fentanyl remains the dominant driver of these deaths. (Discover Health Group)

Local coverage has repeatedly emphasized that fentanyl was responsible for the vast majority of overdose deaths in 2023–2024, even as the overall numbers eased off their peak. (WMUR)

So, yes: the system is finally bending the overdose curve down. But it’s doing that in an environment where a single counterfeit pill or line of powder can kill someone with a few stray micrograms.

Treatment use: New Hampshire is actually an outlier — in a good way

A 2025 report from the New Hampshire Fiscal Policy Institute (NHFPI) looked at Medicaid data and found:

In 2021, 12.9% of New Hampshire’s Medicaid population received substance use disorder (SUD) treatment, versus a national average of 7.9%.
7.5% of NH Medicaid enrollees were treated for opioid use disorder (OUD) — the highest rate in the country, tied with West Virginia among Medicaid expansion states.

That means: more low-income Granite Staters actually make it into treatment than in most other states.

Capacity: plenty of outpatient, thin residential, and uneven geography

The federal 2023 National Substance Use and Mental Health Services Survey (N-SUMHSS) paints this snapshot of the treatment landscape in New Hampshire: (SAMHSA)

91 substance use treatment facilities reported data, serving 15,800 clients on a single day in March 2023.
85 facilities (93%) offer outpatient treatment, while only 12 facilities (13%) offer non-hospital residential care with 303 designated residential beds.
Residential utilization was about 76%, suggesting the beds that exist are generally used, but there aren’t many to begin with.
67 facilities (74%) provide methadone/buprenorphine or naltrexone; 71 facilities (78%) offer buprenorphine/naloxone, indicating broad MOUD capacity.

So capacity isn’t zero-sum scarcity — but it’s heavily skewed toward outpatient care, with residential spots limited and clustered.

The Doorways: one front door, uneven experiences

The state’s Doorway system — nine regional hubs that serve as a “no wrong door” access point — has become the backbone of how people actually enter treatment:

Since 2019, the Doorways have served about 56,818 individuals, including family members seeking information.
By 2024, roughly 16,920 people had received clinical evaluations, and 28,127 had been referred to treatment through Doorway hubs.
Naloxone distribution through Doorways exploded from 9,190 kits in 2019 to 38,388 kits in 2024, over a 300% increase.

But one key detail matters for outcomes: speed to medication.

A 2023 evaluation of the Doorway system found that while most locations could provide medications for opioid use disorder (MOUD) or referrals within 24–72 hours, the Berlin Doorway in the North Country had waits of up to two weeks for MOUD — exactly the kind of delay that gets people killed in the fentanyl era.

So access is real — but geographically uneven, and dangerously slow in some of the most rural areas.

3. Retention, Relapse, and Readmission: Are People Staying in Care?

If you want to know whether a system is working, you don’t just count how many people pass through the front door. You watch who stays and what happens next.

What the Medicaid 1115 SUD waiver tells us

New Hampshire’s Medicaid program runs a Section 1115 “Substance Use Disorder Treatment and Recovery Access” demonstration, which allows federal Medicaid dollars to pay for short-term SUD treatment in Institutions for Mental Disease (IMDs), like residential programs. (Medicaid)

The state’s recent summative evaluation of this waiver shows:

Emergency department (ED) visits fell in the 90 days after an IMD stay, compared with the 90 days before admission, with declines statistically significant in multiple years. (Medicaid)
The percentage of Medicaid members who had SUD treatment visits at 45, 90, 135, and 180 days after IMD discharge increased significantly compared with baseline — i.e., retention in ongoing treatment improved. (Medicaid)
At the same time, IMD readmission rates within 30 days actually increased over baseline in most years, suggesting cycling back into higher-intensity care remained common. (Medicaid)

Translation: for Medicaid enrollees who land in a residential program, New Hampshire’s system is better at linking them to some form of follow-up care and keeping them somewhat connected, and they’re less likely to boomerang straight back into the ED. But a lot of people still churn in and out of high-level treatment.

National context: retention in MOUD is hard everywhere

A rapid review and meta-analysis of opioid agonist treatment (methadone, buprenorphine) found 12-month retention rates ranging from about 20% to over 80%, with pooled estimates roughly in the 50–65% range, depending on medication and study type. Retention was generally higher for methadone than buprenorphine. (BioMed Central)

The National Institute on Drug Abuse (NIDA) is blunt: opioid use disorder is a chronic, relapsing illness, and even with medications, many people will cycle in and out of treatment. But MOUD significantly reduces overdose deaths and relapse risk compared with no medication. (NIDA)

So when we see New Hampshire’s Medicaid data showing better retention and fewer ED visits after residential episodes — but stubborn readmissions — that’s not a uniquely New Hampshire failure. That’s a sign the state is roughly in line with a national reality: MOUD and continued care help, but we’re still far from sustained remission for most people.

What we don’t really know: relapse and life outcomes

Here’s the uncomfortable truth: outside Medicaid claims and a handful of program evaluations, New Hampshire does not systematically track what happens to people 12, 24, or 36 months after they touch the treatment system:

No statewide public dashboard for relapse rates by program or medication.
No standardized reporting on housing, employment, or criminal legal outcomes post-treatment.
Very limited transparent data on comparative outcomes between, say, an intensive outpatient program plus buprenorphine vs. residential abstinence-only care.

In other words, the most important part of the story — long-term recovery — is mostly anecdote and siloed internal data.

4. Waitlists, Access, and the Reality Behind “No Wrong Door”

Officials will often reassure reporters that New Hampshire has minimal waitlists, especially since the launch of The Doorway and the Medicaid waiver.

The 1115 evaluation backs some of that up: in provider surveys, most reported treatment wait times of 0–24 hours across levels of care, though they flagged withdrawal management (detox) as a weak spot. (Medicaid)

But zoom out a little and the picture gets more complicated.

Capacity is not the same thing as effective access

The N-SUMHSS profile shows: (SAMHSA)

Only 12 residential facilities with 303 beds in the entire state.
Most facilities are outpatient-only.
Just 38 facilities (about 42%) receive public funding or grants, meaning a substantial chunk of the system is financially oriented toward insured and cash-pay patients.

Overlay that with NHFPI’s Doorway evaluation: rural residents in places like Conway or Colebrook may have to drive an hour or more to reach in-person Doorway services or higher-level care, and some sites had multi-week waits for MOUD.

So it’s technically true that anyone can call 211 and reach “a Doorway.” But speed, distance, and follow-through vary dramatically by geography. A same-day telehealth evaluation is not the same as same-day buprenorphine in hand.

Detox and withdrawal management: the persistent weak link

Providers in the Medicaid evaluation specifically highlighted withdrawal management access as a gap, even as they described overall network access as “good.” (Medicaid)

In practice, that often means:

People in acute withdrawal end up in EDs that are not designed as detox units, or
They’re bounced between EDs, short-stay detox facilities, and outpatient clinics struggling to coordinate MOUD induction — a coordination problem that gets brutal when fentanyl is involved.

Which brings us to the central villain of the modern system.

5. How Fentanyl Changed the Game — and Broke Old Treatment Rules

Fentanyl is not just “a stronger opioid.” It has fundamentally altered both overdose risk and the clinical realities of treatment.

Overdose risk: tiny margin for error

New Hampshire’s Drug Overdose Fatality Review Commission and related analyses are clear: from 2019 to 2021, overdose deaths surged nationally by 51%, and fentanyl and its analogs were the key driver both nationally and in New Hampshire. (NH DHHS)

By 2023–2024, fentanyl accounted for the vast majority of overdose deaths in the state. (WMUR)

That makes familiar problems — like gaps between detox and follow-up, or multi-day waits for MOUD — orders of magnitude more deadly.

Clinical reality: higher tolerance, trickier inductions, more dropouts

Several emerging lines of research point to a new reality for MOUD in the fentanyl era:

Fentanyl markedly increases opioid tolerance, meaning standard methadone protocols can under-dose patients, leaving them in withdrawal or craving and more likely to drop out. (BioMed Central)
A recent review of methadone in the fentanyl era notes that traditional dosing schedules may be too conservative, delaying symptom relief and undermining retention, and calls for regulatory changes to make methadone more accessible and flexible. (SpringerLink)
A cohort study of buprenorphine in Rhode Island during widespread fentanyl found that higher daily doses (over 16 mg, up to 24–32 mg) were associated with longer treatment retention, suggesting official or insurer-imposed dose caps may be undermining outcomes. (JAMA Network)
Clinical guidance on buprenorphine induction has had to evolve to address precipitated withdrawal in people with heavy fentanyl exposure, including higher “macro-dosing” or micro-dosing strategies — all of which increase complexity and opportunities for dropout. (Default)

All of that interacts badly with the system-level issues already described:

Rural waits for MOUD.
Limited detox capacity.
Insurance constraints on dose and formulation.
Fragmentation between EDs, Doorways, OTPs (methadone clinics), and residential programs.

If you try to run 20th-century opioid treatment protocols (built for heroin and pill misuse) against 21st-century illicit fentanyl, you get exactly what New Hampshire has: high rates of treatment initiation and MOUD availability on paper, but persistent churn, dropouts, and preventable deaths.

6. Medicaid vs. Private-Pay: Same System, Different Reality

New Hampshire is an expansion state, and Medicaid is absolutely central to its SUD treatment system.

Medicaid coverage is broad — but not frictionless

The NH DHHS Substance Use Disorder (SUD) Benefit for Medicaid recipients covers a wide range of services: detox/withdrawal management, outpatient and intensive outpatient programs, partial hospitalization, residential treatment, peer recovery, and recovery support services, all delivered through Medicaid-enrolled providers. (NH DHHS)

On top of that, NHFPI documents more than $834.7 million in SUD-related spending from 2014 to 2024, with annual spending increasing about 450% over that decade, largely driven by Medicaid and federal grants. (New Hampshire Fiscal Policy Institute)

So on the Medicaid side:

Coverage is generous on paper.
The 1115 SUD waiver shows improved access, better retention, and fewer ED visits post-discharge for Medicaid members. (Medicaid)

But that doesn’t mean Medicaid and privately insured patients experience the system the same way.

Who gets seen, and on what terms?

From the N-SUMHSS state profile: (SAMHSA)

90.1% of NH facilities accept Medicaid, while 97.8% accept private health insurance and 98.9% accept cash/self-pay.
65.9% offer a sliding fee scale, and 45.1% provide free or minimal payment options for those who cannot pay.
Only 41.8% of facilities receive any government funding or grants, meaning most rely primarily on insurance and private payments.

Separately, a rehab-industry analysis of the state’s treatment market found: (Rehab.com)

170 addiction centers in New Hampshire overall.
100 accept Medicaid, 102 accept private insurance, and 108 accept cash payment.
The average cost of drug rehab in the state is about $58,777, and no centers were listed as offering completely free treatment.
New Hampshire ranked 42nd nationally for affordability of drug rehab.

So while Medicaid opens doors, the more market-driven parts of the system still tilt toward private insurance and cash-pay clients — whether in terms of amenities, pace of admission, or discretion about who gets a bed.

Even when Medicaid technically covers a service, managed care rules, prior authorizations, and lower reimbursement rates can make some providers slow-walk or quietly disfavor Medicaid slots while keeping higher-paying private beds available.

That’s hard to prove program by program, but the incentives are real, and they show up in who ends up sent to out-of-state residential, who gets stuck on outpatient-only tracks, and who gets more flexible, individualized care.

7. So… Does New Hampshire’s Treatment System “Work”?

If you want a one-sentence answer: New Hampshire’s addiction treatment system works better than most in some important ways, but in the age of fentanyl it is still losing too many people and measuring too little of what matters.

Concretely:

Where it’s working:

More people in treatment: A higher share of Medicaid enrollees receive SUD and OUD treatment than almost anywhere else in the U.S.
MOUD availability: The majority of facilities offer buprenorphine and other MOUD options, and Doorways plus SOR-funded initiatives have expanded access and naloxone distribution. (SAMHSA)
Improved post-discharge outcomes for Medicaid IMD patients: ED visits drop after residential stays; retention at 45–180 days has improved versus baseline. (Medicaid)
Overdose deaths are finally declining, not spiking, despite fentanyl’s dominance. (Discover Health Group)

Where it’s failing or fragile:

Readmission and churn remain high; people cycle in and out of residential care, detox, and the ED.
Rural access is uneven; wait times for MOUD in parts of the North Country can be dangerously long.
Detox/withdrawal management is a weak link, frequently flagged by providers and patients.
Medicaid vs private-pay gaps still shape who gets faster access and higher-end options, even if formally both cover SUD treatment.
The system rarely tracks long-term outcomes like relapse, housing, employment, or criminal-legal involvement in a way the public can see or policymakers can be held to.

And over all of it, fentanyl acts like a multiplier for every weakness — every delay, every low-dose protocol, every missed follow-up call.

This is not a system in failure, but it is a system just barely keeping pace with a drug supply that’s evolving faster than policy.

8. What Would “Working” Look Like in a Fentanyl State?

If New Hampshire wants to move from “less bad than it used to be” to “this actually works”, the next wave of reform has to go well beyond “more funding.”

Here are the hard-nosed changes that would actually move outcomes:

1. Make retention and relapse real metrics, not vibes

Require every state-funded treatment provider (including those paid via Medicaid, grants, and settlement funds) to report standardized 6-, 12-, and 24-month outcomes:
- Retention in MOUD or other evidence-based care.
- Overdose events.
- Re-arrest/re-incarceration.
- Housing stability.
Publish facility-level data (appropriately de-identified for patients) to let policymakers, journalists, and families see which programs actually keep people alive and functioning.

2. Guarantee same-day MOUD access statewide

If fentanyl is the baseline, “I’ll put you on buprenorphine next week” is malpractice at the system level.

Use Medicaid, grant, and settlement dollars to fund same-day MOUD capacity in every region, including:
- Mobile induction teams.
- Telehealth induction with local pharmacy dispensing.
- Extended hours at OTPs and prescribing clinics.
Tie state contracts and waivers to measurable performance: time from initial contact (e.g., Doorway or ED) to first dose of MOUD, with clear targets (e.g., 24 hours in urban regions, 48 hours max in rural areas).

3. Rewrite dosing and practice assumptions for the fentanyl era

Encourage regulators and payers to align with emerging evidence that many patients in a fentanyl environment need higher buprenorphine and methadone doses to remain stabilized and retained. (JAMA Network)
Work with Medicaid managed care organizations (Well Sense, NH Healthy Families, AmeriHealth Caritas) to lift or rationalize dose caps and prior auth barriers for MOUD where clinically indicated.
Expand training and technical assistance for clinicians on fentanyl-aware induction protocols, including micro-dosing and macro-dosing approaches with strong safety and follow-up.

4. Use settlement and grant money for structural fixes, not pilot-of-the-month

NHFPI’s review shows tens of millions in opioid settlement funds already expended or obligated, with more to come.

Those dollars should be treated as once-in-a-generation capital for system redesign, not temporary project cash:

Build regional recovery housing linked tightly to MOUD and employment supports.
Fund transportation and childcare as core clinical enablers, not afterthoughts.
Create permanent community-based MOUD access in jails, prisons, and re-entry — the highest-risk transitions in the state.

5. Enforce parity where it actually matters: network adequacy and timeliness

New Hampshire has long had formal mental health and SUD parity rules for Medicaid, meaning behavioral health coverage must be on par with medical/surgical coverage. (NH DHHS)

The state should push that standard into how quickly private insurers and Medicaid MCOs must provide MOUD and higher levels of care:

Time-to-appointment standards for SUD comparable to acute medical issues.
Network adequacy standards that consider geography, MOUD capacity, and levels of care, not just “number of providers on paper.”

This isn’t about “more funding” in the abstract; it’s about shifting power from plans and institutions to outcomes and patients.

9. Suggested Visuals for GraniteStateReport.com

To make this story hit harder on the site, you could drop in visuals like:

Chart: Overdose deaths in NH, 2014–2023, with fentanyl share highlighted.
Map: Doorway locations overlaid with counties showing highest overdose death rates.
Bar graph: Share of NH Medicaid population in SUD/OUD treatment vs U.S. average.
Table: Facility payment types (Medicaid vs private vs cash) and percent offering MOUD. (SAMHSA)

10. Related Videos and Resources

Medications for Opioid Use Disorder – NIDA explainer video
YouTube: https://www.youtube.com/watch?v=jn3EsvHlvMo (YouTube)

Facing Fentanyl – Short documentary on fentanyl’s impact and community responses
YouTube: https://www.youtube.com/watch?v=0qklvXHWtyo (YouTube)

NIDA Animations playlist – Quick, high-quality explainers on addiction science
YouTube: https://www.youtube.com/playlist?list=PLE4ZNGaomJBn0XlRD4NvDrXA4r31G3shx (YouTube)

And for readers hungry for primary sources:

NHFPI – “Substance Use Disorder Services Funding in New Hampshire” (2025) – Detailed breakdown of SUD spending, Doorways, and outcomes.
NH DHHS – SUD Benefit for Medicaid Recipients: Detailed description of what Medicaid covers. (NH DHHS)
CMS/NH DHHS – SUD 1115 Demonstration Summative Evaluation (2024): The backbone of the retention and ED-use findings. (Medicaid)
SAMHSA – 2023 N-SUMHSS New Hampshire State Profile: Facility capacity, services, and payment options. (SAMHSA)
NHFPI & BDAS data links – For overdose trends, SOR funding, and Doorway performance. (FHC)

Bottom Line

New Hampshire has done a lot right: expanded Medicaid, built The Doorway, embraced MOUD, and poured serious money into SUD care. The system does connect more people to treatment than most states and does prevent deaths that would otherwise happen.

But in a fentanyl-dominated market, a system can be both better than average and nowhere near good enough.

If Granite Staters want to move from “less death” to “real recovery,” the next phase has to be ruthlessly focused on retention, speed to MOUD, rural equity, and long-term outcomes — and brutally honest about where the current system comes up short.